Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism ; volume:9 ; number:1 ; day:15 ; month:4 ; year:2019 ; pages:1-9 ; date:12.2019
Scientific reports ; 9, Heft 1 (15.4.2019), 1-9, 12.2019
- Creator
-
Sjöström, Henrik
Surova, Yulia
Nilsson, Markus
Granberg, Tobias
Westman, Eric
van Westen, Danielle
Svenningsson, Per
Hansson, Oskar
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-42565-4
- URN
-
urn:nbn:de:101:1-2019042816153831159481
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sjöström, Henrik
- Surova, Yulia
- Nilsson, Markus
- Granberg, Tobias
- Westman, Eric
- van Westen, Danielle
- Svenningsson, Per
- Hansson, Oskar
- SpringerLink (Online service)
Other Objects (12)
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
Novel insights regarding the measurement properties of the SCOPA-AUT
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Towards a unified protocol for handling of CSF before β-amyloid measurements
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Factors associated with fear of falling in people with Parkinson’s disease
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
Novel insights regarding the measurement properties of the SCOPA-AUT
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Towards a unified protocol for handling of CSF before β-amyloid measurements
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Factors associated with fear of falling in people with Parkinson’s disease
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
Novel insights regarding the measurement properties of the SCOPA-AUT
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Towards a unified protocol for handling of CSF before β-amyloid measurements
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Factors associated with fear of falling in people with Parkinson’s disease